| [1] |
Fujii H, Yoshida M, Gong ZX, et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity[J].Cancer Res, 2000, 60(1):114-120.
|
| [2] |
Amant F, Vloeberghs V, Woestenborghs H, et al. Transiition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis[J].Gynecol Oncol, 2003, 90(2):372-377.
|
| [3] |
van Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center[J]. Cancer, 2004, 100(10):2148-5315.
|
| [4] |
Barnholtz-Sloan J, Bryant C, Morris R, et al. Epidemiology and survival of women diagnosed with malignant mixed mullerian tumors of the ovary (OMMMT)[J]. Proc Am Soc Clin Oncol, 2003, 22:467s.
|
| [5] |
Sood AK, Sorosky JI, Gelder MS, et al. Primary ovarian sarcoma-analysis of prognostic variables and the role of surgical cytoreduction[J]. Cancer, 1998, 82:1731-1737.
|
| [6] |
Jonson AL, Bliss RL, Truskinovsky A, et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma[J]. Gynecol Oncol, 2006, 100:561-564.
|
| [7] |
Barnholtz-Sloan J, Bryant C, Morris R, et al. Epidemiology and survival of women diagnosed with malignant mixed mullerian tumors of the ovary (OMMMT)[J]. Proc Am Soc Clin Oncol, 2003, 22:467s.
|
| [8] |
Rauh-Hain AJ, Grodwon WB, Rodriguez N, et al. Carcinosarcoma of the ovary: A case control study[J]. Gynecol Oncol, 2011, 121:477-481.
|
| [9] |
Rutledge TL, Gold MA, McMeekin DS, et al. Carcinosarcoma of the ovary:A case series[J]. Gynecol Oncol, 2006, 100:128-132.
|
| [10] |
Duska LR, Garrett A, Eltabakh GH, et al. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary[J]. Gynecol Oncol, 2002, 85:459-463.
|
| [11] |
Silasi DA, Illuzzi JL, Kelly MG, et al. Carcinosarcoma of the ovary[J]. Int J Gynecol Cancer, 2008, 18:22-29.
|
| [12] |
Mano MS, Rosa DD, Azambuja E, et al. Current management of ovarian carcinosarcoma[J]. Int J Gynecol Cancer, 2007, 17:316-324.
|
| [13] |
Cantrell LE, Van Le L. Carcinosarcoma of the ovary: A review[J]. Obstet Gynecol Surv, 2009, 64:673-680.
|
| [14] |
Duska LR, Garrett A, Eltabbakh GH, et al. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary[J]. Gynecol Oncol, 2002, 85:459-463.
|
| [15] |
Cicin I, Saip P, Eralp Y, et al. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum[J]. Gynecol Oncol, 2008, 108:136-140.
|
| [16] |
Leiser AL, Chi DS, Ishill NM, et al. Carcinosarcoma of the ovary treated with platinum and taxane: The Memorial Sloan-Kettering cancer center experience[J]. Gynecol Oncol, 2007, 105:657-661.
|
| [17] |
Crotzer DR, Wolf JK, Gano JB, et al. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary[J]. Gynecol Oncol, 2007, 105:399-403.
|
| [18] |
Sit AS, Price FV, Kelley JL, et al. Chemotherapy for malignant mixed mullerian tumors of the ovary[J]. Gynecol Oncol, 2000, 79:196-200.
|
| [19] |
Kyoung-Chul C, Jae-Joon K, Dae-Yeon K, et al.Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas:A single center experiencev[J]. Gynecol Obstet Invest, 2011, 72:208-214.
|